PBM v. Mead Johnson
This article was originally published in The Tan Sheet
Executive Summary
Infant formula litigation settled out of court, Mead parent Bristol-Myers Squibb announces in third quarter 10Q filed recently with SEC. Although details of Oct. 12 settlement are confidential, filing notes Mead recorded a charge of "$42 mil. for settlement of litigation over promotional claims brought by a distributor of store brand infant formula." Mead already had ceased distribution of the two ads questioned by PBM lawsuit and sent roughly 90,000 corrective letters alerting pediatricians about the misleading information (1"The Tan Sheet" May 7, p. 13). PBM says financial settlement represents "consideration paid for damages done"...
You may also be interested in...
Mead Johnson Enfamil Ads Withdrawn After Restraining Order
Mead Johnson distributed roughly 90,000 letters in late April informing pediatricians its previously circulated literature regarding store-brand infant formulas contained incorrect information about calcium and folic acid levels.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.